Skip to main content

Table 2 Treatment categories and in-hospital mortality in patients with different MxA levels

From: Association of human myxovirus resistance protein A with severity of COVID-19

 

Low-MxA < 400 μg/L (N = 36)

Intermediate MxA 400–799 μg/L (N = 73)

High MxA ≥ 800 μg/L (N = 159)

p-value

Respiratory support, n/N (%)

   

 < 0.001

 No respiratory support

22/36 (61%)

26/73 (36%)

28/158 (18%)

 

 Supplemental oxygen (≤ 15 L/min)

7/36 (19%)

27/73 (37%)

75/158 (48%)

 

 HFNC/NIV/Intubation

7/36 (19%)

20/73 (27%)

55/158 (35%)

 

ICU, n/N (%)

   

0.329

 No

28/36 (78%)

53/73 (73%)

101/159 (64%)

 

 Yes

4/36 (11%)

14/73 (19%)

35/159 (22%)

 

 DNR

4/36 (11%)

6/73 (8%)

23/159 (15%)

 

Corticosteroids, n/N (%)

17/36 (47%)

45/73 (62%)

123/159 (77%)

 < 0.001

In hospital mortality, n/N (%)

1/36 (3%)

2/73 (3%)

10/159 (6%)

0.416

  1. HFNC high-flow nasal cannula, NIV non-invasive ventilation, ICU intensive care unit, DNR do-not-resuscitate, MxA human myxovirus resistance protein A
  2. P-values of frequencies were tested with Pearson's chi-squared test